Market Access

In the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.

A new and more compelling strategy must be crafted to engage critics on drug pricing and bolster biopharmaceuticals as a leader in technological innovations that lower health costs overall.

Pharm Exec sits down with prominent biotech investment strategist, Tony Gibney, to better gauge today’s state of play in this critically innovative segment of the life sciences industry.

A response to the therapeutic potential of using bacteriophages as antibiotics - though doubtful phages can be applied as antibiotics have, they do offer mighty weapons against threats of antibiotic resistance.

Ed Schoonveld highlights the wait confronting lung cancer patients seeking Opdivo in the UK. Can we find room for compromise?

A non-antibiotic bactericidal treatment for humans was first proven effective in 1919. Ansis Helmanis asks why they are not commercially available in the United States.

Commercial success for pharma brands now demands proactive strategies and interventions

What can companies do for an encore when their own blockbuster product is threatened by branded or generic competitors?

Susan Crowley reviews the hotly debated agenda items from last month's World Health Assembly (WHA) in Geneva, Switzerland.

NICE's proposed Innovation Office emerges with a new name. Leela Barham reports.

What’s new in the growing field of global market access?

Pharm Exec's 2015 Brand of the Year Sovaldi and Harvoni are huge game-changers for Hepatitis C, but the big-picture impact will come down to how well the market aligns pricing, distribution, and access toward the broader goal of making sure that those patients who need the cure, get the cure.

Insurers and payers demand lower prices-along with quality and innovation.

Positive early stage trial results for Biogen’s aducanumab has renewed hope for effective solutions for Alzheimer's Disease, but many challenges remain in finding and funding new treatment, writes Ed Schoonveld.

As more new products vie for payer and prescriber attention, the stakes around launch success are higher than ever. Stan Bernard outlines the key traps to avoid in getting things right - when it really counts.

I offered up a prediction: that the future of the biopharmaceutical business depended on how managers fared on five key measures of performance.

Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market.

Andrea Sobrio and Dr. Sandra Schoenes examine the market access challenges and opportunities specifically for premium, specialty inpatient products in the LatAm region.

Transparency initiatives are multiplying, affecting research, marketing and compliance.

The growing clamor for broader access to information on health care practices, policies and costs is affecting research, marketing and compliance, writes Jill Wechsler.

Pharm Exec convenes a diverse panel of experts to identify the key markers of common ground: its time, people, and money against that greatest intangible-hope.

Real-world pharmacoeconomic data can provide critical insight for maximizing US market access and oncology product differentiation, and should be central to the overall brand strategy of any oncology product

Patient access is the new driver of change and progress in healthcare marketing, says a senior industry player in market development.

A proactive approach to talent and organization planning is the hidden trump card in prevailing with payers.

Unified payer research planning is of top import.

A comparative effectiveness study on the two presidential candidates.

The prospect that antiretroviral drugs could prevent HIV infection in high-risk populations was the big news emerging from last month’s International AIDS Conference in Washington, DC.

Marck McClellan, MD, Director, Engelberg Center for Health Reform, Brookings Institute

Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies

Pharma can be an insular industry, with limited capacity to gaze beyond its own narrow frame of vision